Yamana Satoshi, Hasegawa Eiichi, Takeda Atsunobu, Yawata Nobuyo, Sonoda Koh-Hei
Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Int Ophthalmol. 2023 Mar;43(3):937-944. doi: 10.1007/s10792-022-02495-z. Epub 2022 Sep 4.
To evaluate long-term outcomes of infliximab (IFX) treatment in patients with Behçet's disease (BD)-associated uveitis.
We retrospectively analyzed the cases of patients with BD-associated uveitis treated with IFX for > 5 years. We compared the numbers of ocular inflammatory attacks, ocular disease activities, and visual acuity before and after the initiation of IFX treatment.
The 24 patients were 20 men and 4 women. Their mean age at the initiation of IFX treatment was 37.3 ± 9.2 years. The mean term from the initiation of IFX treatment was 10.3 ± 2.4 years. The average number of ocular inflammatory attacks was 5.4 ± 2.1 per 12 months before the IFX treatment and significantly lower at 0.83 ± 0.96 per 12 months after the initiation of IFX treatment (p < 0.05). We used a scoring system for BD-associated uveitis named the Behçet's disease ocular attack score 24 (BOS24) to estimate the changes in ocular disease activities between before and after initiation of IFX treatment. The average score decreased significantly from 7.58 ± 2.77 to 2.55 ± 2.74 after the initiation of IFX treatment (p < 0.05). Even after > 5 years of the treatment, both the number of ocular attacks and the BOS24 score kept decreasing. The visual acuity in 42 of 48 eyes (24 patients) was improved or maintained.
IFX was effective for controlling ocular inflammatory attacks and diminishing ocular disease activities in patients with BD-associated uveitis, and it maintained the patients' visual acuity.
评估英夫利昔单抗（IFX）治疗白塞病（BD）相关葡萄膜炎患者的长期疗效。
我们回顾性分析了接受IFX治疗超过5年的BD相关葡萄膜炎患者的病例。比较了IFX治疗开始前后眼部炎症发作次数、眼部疾病活动度和视力。
24例患者中，男性20例，女性4例。IFX治疗开始时的平均年龄为37.3±9.2岁。IFX治疗开始后的平均时间为10.3±2.4年。IFX治疗前每12个月眼部炎症发作的平均次数为5.4±2.1次，IFX治疗开始后显著降低，为每12个月0.83±0.96次（p<0.05）。我们使用一种名为白塞病眼部发作评分24（BOS24）的BD相关葡萄膜炎评分系统来评估IFX治疗开始前后眼部疾病活动度的变化。IFX治疗开始后，平均评分从7.58±2.77显著降至2.55±2.74（p<0.05）。即使经过5年以上的治疗，眼部发作次数和BOS24评分仍持续下降。48只眼中的42只（24例患者）视力得到改善或维持。
IFX对控制BD相关葡萄膜炎患者的眼部炎症发作和减轻眼部疾病活动度有效，并能维持患者的视力。
